tradingkey.logo
tradingkey.logo
検索

Harrow Inc

HROW
ウォッチリストに追加
41.500USD
-1.180-2.76%
終値 06/25, 16:00ET15分遅れの株価
1.55B時価総額
損失額直近12ヶ月PER

詳細情報 Harrow Inc 企業名

Harrow, Inc. is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the North American market. The Company offers a comprehensive portfolio of prescription and non-prescription pharmaceutical products. It owns commercial rights to portfolios of branded ophthalmic pharmaceutical products in North America, all of which are marketed under the Harrow name. It owns and operates ImprimisRx, an ophthalmology-focused pharmaceutical-compounding business. It owns United States commercial rights to various products: IHEEZO, VEVYE, TRIESENCE, VIGAMOX, ILEVRO, FLAREX, NATACYN, ZERVIATE, BYQLOVI and others. VIGAMOX (moxifloxacin hydrochloride ophthalmic solution) 0.5%, a fluoroquinolone antibiotic eye drops for the treatment of bacterial conjunctivitis caused by susceptible strains of organisms. IHEEZO (chloroprocaine hydrochloride ophthalmic gel) 3% is a low-viscosity gel indicated for ocular surface anesthesia.

Harrow Incの企業情報

企業コードHROW
会社名Harrow Inc
上場日Feb 08, 2013
最高経営責任者「CEO」Mullery (Frank)
従業員数382
証券種類Ordinary Share
決算期末Feb 08
本社所在地1A Burton Hills Blvd
都市NASHVILLE
証券取引所NASDAQ OMX - NASDAQ BASIC
United States of America
郵便番号37215
電話番号16157334731
ウェブサイトhttps://www.harrow.com/
企業コードHROW
上場日Feb 08, 2013
最高経営責任者「CEO」Mullery (Frank)

Harrow Incの経営陣

会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Mark L. Baum, J.D.
Mr. Mark L. Baum, J.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
3.00M
+0.33%
Mr. Andrew R. Boll
Mr. Andrew R. Boll
President, Chief Financial Officer, Company Secretary
President, Chief Financial Officer, Company Secretary
814.68K
+0.43%
Dr. Adrienne L. Graves, Ph.D.
Dr. Adrienne L. Graves, Ph.D.
Independent Director
Independent Director
19.80K
+5.05%
Mrs. Lauren P. Silvernail
Mrs. Lauren P. Silvernail
Independent Director
Independent Director
19.80K
+5.05%
Mr. Perry J. Sternberg
Mr. Perry J. Sternberg
Lead Independent Director
Lead Independent Director
--
--
Mr. Amir Shojaei, Ph.D.
Mr. Amir Shojaei, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Mr. Randall E. Pollard, CPA
Mr. Randall E. Pollard, CPA
Chief Accounting Officer
Chief Accounting Officer
--
--
Mr. Frank Mullery
Mr. Frank Mullery
Chief Executive Officer of ImprimisRx
Chief Executive Officer of ImprimisRx
--
--
会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Mark L. Baum, J.D.
Mr. Mark L. Baum, J.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
3.00M
+0.33%
Mr. Andrew R. Boll
Mr. Andrew R. Boll
President, Chief Financial Officer, Company Secretary
President, Chief Financial Officer, Company Secretary
814.68K
+0.43%
Dr. Adrienne L. Graves, Ph.D.
Dr. Adrienne L. Graves, Ph.D.
Independent Director
Independent Director
19.80K
+5.05%
Mrs. Lauren P. Silvernail
Mrs. Lauren P. Silvernail
Independent Director
Independent Director
19.80K
+5.05%
Mr. Perry J. Sternberg
Mr. Perry J. Sternberg
Lead Independent Director
Lead Independent Director
--
--
Mr. Amir Shojaei, Ph.D.
Mr. Amir Shojaei, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--

よくある質問

Harrow Incの上位5名の株主は誰ですか?

Harrow Incの上位5名の株主は以下のとおりです。Mr. Mark L. Baum, J.D.

Harrow Inc(HROW)の株式を保有している機関の数はいくつですか?

2026Q1時点で、Harrow Incの株式を保有している機関は418社あり、保有株式の総市場価値は約24.67Mで、全体の66.17%を占めています。2025Q4と比較して、機関の持ち株は347374.00増加しています。
KeyAI